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A B S T R A C T
S100B protein concentrations correlate with the severity and outcome of brain damage after brain
injuries, and have been shown to be markers of blood–brain barrier damage. In children elevated S100B
values are seen as a marker of damage to astrocytes even after mild head injuries. S100B proteins may
also give an indication of an ongoing pathological process in the brain with respect to febrile seizures (FS)
and the likelihood of their recurrence. To evaluate this, we measured S100B protein concentrations in
serum and cerebrospinal ﬂuid from 103 children after their ﬁrst FS. 33 children with acute infection
without FS served as controls for the serum concentrations. In the FS patients the mean S100B
concentration in the cerebrospinal ﬂuid samples was 0.21 mg/L and that in the serum samples 0.12 mg/L.
The mean serum concentration in the controls was 0.11 mg/L (difference 0.01 mg/L, 95% conﬁdence
interval 0.02 to 0.04 mg/L, P = 0.46). There was a correlation between age and serum S100B
concentration (r = 0.28, P = 0.008) in children under four years, but S100B concentrations did not
predict the clinical severity of the FS nor their recurrence. There was no correlation between time of
arrival at the hospital after FS and S100B concentration in serum (r = 0.130, P = 0.28) or in cerebrospinal
ﬂuid samples (r = 0.091, P = 0.52). Our ﬁndings indicate that FS does not cause signiﬁcant blood–brain
barrier openings, and increase the evidence that these seizures are relatively harmless for the developing
brain.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Febrile seizures (FS) are the most common form of childhood
seizures, usually appearing between 6 months and 6 years of age.1
They are benign and affect about 2–5% of all children, and
recurrences are common.2 The pathomechanisms of FSs are not
known. Since Na+ channel disorders, in which FSs are seen together
with generalized epilepsy (GEFS+), resemble FSs, it has been
hypothesized that FSs are transient ion channel disorders which
are dependent on the developmental stage of the brain.3
The S100 proteins, of which there are more than 20, form the
largest group of EF-hand Ca2+-binding proteins. They are
regulatory and are tissue and cell-speciﬁc. Concentrations of
S100B proteins correlate with the severity of brain damage and
with the outcome after brain injury.4 Elevated S100B levels are
detected as a marker of injury to the astrocytes even after mild
head injury,5 in children with septic encephalopathy and in
newborns after prolonged labour,6 and they are also associated
with a number of other diseases, e.g. migraine, epilepsy,
cardiomyopathy, cancer and inﬂammatory and autoimmune
diseases.7* Corresponding author. Tel.: +358 8 3155848; fax: +358 8 3155559.
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doi:10.1016/j.seizure.2011.10.006We hypothesized that S100B proteins may give an indication of
an ongoing pathological process in the brain connected with FS and
could be predictive of recurrences of FSs. We measured the
concentrations of these proteins in children who had had their ﬁrst
FS and control children with febrile infections but without
seizures, comparing serum concentrations between the patients
and controls and correlating them with the severity of FSs and its
recurrences.
2. Materials and methods
The basic population consisted of the 231 patients at the
Department of Pediatrics, University of Oulu who had experienced
their ﬁrst FS and had participated in our previous evaluation of the
efﬁcacy of antipyretics for preventing recurrences during the
period 1997–2003.8 The study was performed according to the
Declaration of Helsinki, and the protocol was found to be ethically
acceptable by the Ethical Committee of the Medical Faculty at the
University of Oulu. Informed consent was obtained from all the
parents. Serum samples were available from 91 of the patients and
from 33 controls with acute febrile infection without seizures
(Table 1), while cerebrospinal ﬂuid (CSF) samples were available
from 74 patients, including 12 for whom we did not have serum
samples. Twenty-ﬁve of the 103 FS patients tested (24%) had FS
among their parents or siblings, 39 had had complex FS and 20 hadvier Ltd. All rights reserved.
Table 1
Demographic characteristics of the patients with a ﬁrst febrile seizure (FS) and the
controls with acute febrile infection without seizure.
Patients Controls
Characteristic Serum (n = 91) CSF (n = 74)a n = 33
Age, years (SD, range) 1.8
(0.8, 0.4–4.0)
1.8
(0.8, 0.4–4.0)
1.4
(0.7, 0.1–3.0)
Female (%) 36 (40) 30 (41) 11 (33)
Simple/complex FS 61/30 46/28 –
Family history of FS, no/yes 57/23 44/17 –
Recurrence of FSb, no/yes 42/16 27/14 –
CSF, cerebrospinal ﬂuid.
a Including 12 patients for whom no serum sample was available.
b Only patients with at least one febrile episode after their ﬁrst FS were analysed.
Table 2
Mean concentrations of S100B protein (mg/L) in serum and cerebrospinal ﬂuid (CSF)
in the patients with febrile seizure (FS), by demographic characteristics.
No Yes Difference 95% CI P-value
Serum
Females (n = 91) 0.12 0.12 0.00 0.04 to 0.04 0.99
Complex FS (n = 91) 0.13 0.11 0.02 0.02 to 0.05 0.35
Family history of
FS (n = 80)
0.13 0.11 0.01 0.03 to 0.06 0.54
Recurrence of FS
(n = 58)a
0.14 0.10 0.04 0.02 to 0.10 0.22
CSFb
Female (n = 74) 0.18 0.26 0.08 0.22 to 0.06 0.27
Complex FS (n = 74) 0.20 0.24 0.04 0.17 to 0.08 0.51
Family history of FS
(n = 61)
0.24 0.21 0.02 0.14 to 0.19 0.77
Recurrence of
FS (n = 41)a
0.20 0.17 0.03 0.11 to 0.16 0.70
CI, conﬁdence interval.
a Only patients with at least one febrile episode after their ﬁrst FS were analysed.
b Including 12 patients for whom no serum samples were available.
Fig. 1. Serum S100B concentrations in patients with febrile seizure, by age.
K. Mikkonen et al. / Seizure 21 (2012) 144–146 145had recurrences of FS (Table 1). FS was considered complex when it
was focal or prolonged (>15 min), or more than one seizure had
occurred within 24 h. Parents were instructed to measure
temperature and to record all seizures in detail. Nurses working
within the study contacted the families by telephone at least once a
month for two years to ensure that we received all the information
needed.8 Only data on patients with at least one febrile episode
after their ﬁrst FS (n = 66) were analysed with regard to the
recurrence of FSs. The median time elapsing between the ﬁrst FS
episode and arrival at the hospital had been 2.4 h (range 0.08–
73 h). Only 4 patients had arrived at hospital after an interval of
15 h. Blood samples were collected as soon as possible after arrival
and the time delay was similar for all the patients, although the
exact times of blood sampling are not available.
2.1. Assays
S100B was analysed using a fully automated LIAISON system
(AB DiaSorin, Bromma, Sweden), an immunoluminometric assay
which detects the b subunit of the S100 protein. The analytical
sensitivity of this method is 0.013 lg/l, the typical intra-assay
precision is below 5% and the inter-assay precision is below 10%.
2.2. Statistics
An unpaired t test was used to analyse differences in continuous
variables between the two groups. Univariate associations
between continuous variables were calculated using Pearson’s
rank correlation coefﬁcients (r). All the data were analysed with
SPSS, version 17.0, for Windows.
3. Results
The mean serum concentration of S100B protein was 0.12 mg/L
among the patients with FS and 0.11 mg/L in the controls
(difference 0.01, 95% conﬁdence interval (CI) 0.02 to 0.04 mg/L,
P = 0.46). The mean S100B value in the CSF of the patients with FS
was 0.21 mg/L. The ratio between the mean CSF and serum S100B
concentrations in patients with FS was 1.75.
There were no signiﬁcant differences in mean serum or CSF
S100B concentrations between the genders, between the patients
with simple and complex FS, between the patients with and
without a family history of FS, or between the patients with
recurrent FS and those with no recurrences (Table 2). The serum
S100B concentration among the patients with complex FS was
0.10 mg/L in those with recurrent FS and 0.12 mg/L in those with no
recurrence (difference 0.03 mg/L, 95% CI 0.1 to 0.05 mg/L,
P = 0.44), The S100B concentrations in the CSF of the same patient
groups were 0.24 mg/L and 0.20 mg/L, respectively (difference
0.04, 95% CI 0.30 to 0.21, P = 0.72).The correlation between the patient’s age and serum S100B
concentration was signiﬁcant (n = 91, r = 0.28, P = 0.008), but no
such correlation was found in the CSF samples (n = 74, r = 0.001,
P = 0.99) (Fig. 1). There was no correlation between time of arrival
at the hospital after FS and S100B concentration in either the serum
(r = 0.130, P = 0.28) or the CSF samples (r = 0.091, P = 0.52).
4. Discussion
The children with FSs in this series did not have elevated serum
S100B values, and the concentration of S100B proteins did not
correlate with the severity of FS, nor did it predict recurrences of
the seizures. Serum S100B protein concentrations decreased with
age, as previously reported among healthy pediatric patients under
the age of 7 years.7,9
S100 protein values in serum and CSF have previously been
reported to be of the same magnitude among adult patients with
recent non-complicated tonic-clonic seizures and controls,7,10
although the absolute CSF concentrations of S100 proteins were
higher than in the present series and the mean serum values
slightly lower. This may be attributable to the difference in age
between the subjects. There are no valid reference values for the
S100B concentration in the CSF of children, but the ratio between
CSF and serum S100B concentrations in adults has been reported
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epilepsy10 and 164 in patients with traumatic brain injury.11 The
corresponding ratio between the mean CSF and serum S100B
concentrations in our series of children was much lower than those
reported in adults, indicating that the children with FS did not have
elevated CSF S100B values. This expected ratio is extrapolated from
adults, of course, and it should be noted that potential differences
may exist for children.
High concentrations of extracellular S100 proteins have been
associated with the activation of cell metabolism, cell death and
disease. An increased concentration of S100B is a feasible indicator
of brain damage,12 even after mild head injury,7 and S100B protein
is also a relevant marker of blood–brain barrier (BBB) openings.13
BBB pathology has frequently been found following mild traumatic
brain injury, and lasting BBB breakdown has been noticed with
increased frequency and extent in patients with posttraumatic
epilepsy.14 Recent studies have indicated a critical role for opening
of the BBB in the pathogenesis of posttraumatic epilepsy,14,15 since
BBB disruption may lead to cortical dysfunction. S100B protein acts
locally in the brain, however, and its short serum half-life, only
approximately 25–113 min, poses challenges for its measurement.
One limitation of this study is the possibility of a temporary small
rise in S100B that may not be detectable any longer by the time of
sampling. However, S100B values measured after brain injury are
many times higher than those found here after FSs,7 even with
similar delays between the event and hospitalization. There was no
correlation between time of arrival at the hospital and S100B
concentration in the serum or CSF of our patients. In fact there are
suggestions in the recent literature that later blood sampling may
even be more speciﬁc for brain injury, since S100B also has
extracranial sources, e.g. bone marrow, and these also peak in the
early period after traumatic injury.7 It should be remembered, of
course, that our clinical samples for S100B measurement in
children were taken from serum and CSF samples but not directly
from the brain. If abnormally high tissue-speciﬁc protein S100B
levels were to exist in the brain, pathological levels of these
proteins would show up in the serum and CSF as well. As it was, the
S100B protein concentrations did not have any clinical prognostic
value for assessing the severity of FS or the likelihood of a
recurrence.
The reason for a correlation between serum S100B concentra-
tion and age, but not between CSF S100B concentration and age is
not known, but the effects of extracranial sources of S100B might
be a possible explanation. All our patients were under four years of
age, and this ﬁnding needs to be tailored to that population,
especially when no signiﬁcant correlation exists between age and
serum S100B levels in adults.Our patients with FS had similar concentrations of S100B to the
control children, indicating that a FS does not cause signiﬁcant BBB
openings, and increasing the evidence that these seizures are
relatively harmless for the developing brain.
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